Menu
Search
|

Menu

Close
X

Moleculin Biotech Inc MBRX.OQ (NASDAQ Stock Exchange Capital Market)

1.75 USD
+0.01 (+0.57%)
As of Jul 21
chart
Previous Close 1.74
Open 1.75
Volume 17,468
3m Avg Volume 41,498
Today’s High 1.78
Today’s Low 1.72
52 Week High 3.40
52 Week Low 1.50
Shares Outstanding (mil) 20.26
Market Capitalization (mil) 49.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.083
FY17
-0.504
FY16
-0.547
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
2.57
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-35.48
14.61
Return on Equity (TTM)
vs sector
-36.21
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2575 W Bellfort Ave Ste 333
HOUSTON   TX   77054-5025

Phone: +1713.3005160

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.

SPONSORED STORIES